Pancreatic Cancer Research

ResearcherTongji HospitalActive in the last 2 years

Chunle Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6088-8043; OpenAlex author ID A5043927228. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2018: 3 papers · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and stabilizing BAG3. Co-author DOI 10.1038/s41418-026-01665-1↗
  2. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-022-01040-w↗
  3. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  4. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. Co-author DOI 10.1186/s13046-022-02491-2↗
  5. Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cell… Co-author DOI 10.7150/ijbs.49514↗
  6. Danthron suppresses autophagy and sensitizes pancreatic cancer cells to doxorubicin. First author DOI 10.1016/j.tiv.2018.10.019↗
  7. TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells. Co-author DOI 10.1186/s13046-019-1343-4↗
  8. PINK1/Parkin-Mediated Mitophagy Regulation by Reactive Oxygen Species Alleviates Rocaglamide A-Induced Apoptosis in Pancreatic Cancer Cells. Co-author DOI 10.3389/fphar.2019.00968↗
  9. Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagy-lysosome pathway via targeting TFEB. Co-author DOI 10.1016/j.taap.2018.08.003↗
  10. A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data. Co-author DOI 10.1038/s41598-018-22493-5↗
  11. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. Co-author DOI 10.1186/s12885-018-4948-7↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Renyi Qin · 10 shared papers, 2018–2026 · strength 1.21
  2. Min Wang · 8 shared papers, 2018–2026 · strength 1.03
  3. Shutao Pan · 8 shared papers, 2018–2026 · strength 1.01
  4. Ruizhi He · 8 shared papers, 2018–2022 · strength 0.75
  5. Taoyuan Yin · 4 shared papers, 2022–2026 · strength 0.67
  6. Xingjun Guo · 6 shared papers, 2018–2022 · strength 0.58
  7. Xiuhui Shi · 6 shared papers, 2018–2022 · strength 0.56
  8. Zhenxiong Zhang · 3 shared papers, 2022–2026 · strength 0.55
  9. Jun Gong · 3 shared papers, 2022–2026 · strength 0.55
  10. Yongkang Shi · 3 shared papers, 2022–2026 · strength 0.55
  11. Yuhui Liu · 5 shared papers, 2019–2022 · strength 0.50
  12. Min Zhou · 5 shared papers, 2018–2019 · strength 0.42
  13. Min Zhou · 2 shared papers, 2023–2026 · strength 0.41
  14. Min Zhou · 3 shared papers, 2021–2022 · strength 0.37
  15. Yan Zhao · 4 shared papers, 2018–2022 · strength 0.35
  16. Li Xu · 3 shared papers, 2019–2021 · strength 0.29
  17. Yu Bai · 1 shared paper, 2026 · strength 0.26
  18. Xu Li · 2 shared papers, 2018–2022 · strength 0.19
  19. Hua Chen · 2 shared papers, 2019 · strength 0.19
  20. Hua Chen · 2 shared papers, 2018–2019 · strength 0.17
  21. Yuhui Liu · 1 shared paper, 2023 · strength 0.16
  22. Yuqing Zhang · 1 shared paper, 2022 · strength 0.12
  23. Min Li · 1 shared paper, 2022 · strength 0.12
  24. Zhijun Zhou · 1 shared paper, 2022 · strength 0.12
  25. Jingxuan Yang · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.